首页> 外文期刊>Molecular pharmaceutics >Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage
【24h】

Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage

机译:溶解/渗透系统在药物发现阶段估算候选药物口服吸收的优势

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

In order to increase the success rate in the development of oral drugs, an in vitro method, which can accurately estimate human oral absorption of a large variety of compounds from solid formulations, is required in the drug discovery stage. A dissolution/permeation (D/P) system is an in vitro system that simultaneously evaluates dissolution and permeation processes of drugs administered orally. In this study, we have investigated the advantages of a D/P system for use in the provisional estimation of human oral absorption of a drug (absorbed fraction, Fa) by applying it in its solid state. The D/P system mounted with a Madin-Darby canine kidney (MDCK) II cell monolayer was used to simultaneously evaluate the dissolved and the permeated amounts (% of dose) of 48 marketed drugs. Slightly modified, fasted-state simulated intestinal fluid (FaSSIF(mod), 8 mL) was used as the apical medium of the D/P system. Each test drug was applied to the apical side of the D/P system as a suspension at one-hundredth of the clinical dose. The apparent permeability coefficient across the MDCK II cell monolayer was estimated in a buffer solution (pH 6.5). The octanol/water distribution coefficient (Log D) was measured at pH 6.5 by a flask shaking method. Transport medium (TM, pH 6.5), a buffer solution removing lecithin and taurocholate from FaSSIF(mod), was used to determine the solubility at 24 h after applying drugs. The solubility in TM was used as a free drug concentration in FaSSIF(mod). A good correlation was obtained between observed human Fa and the permeated amount in the D/P system. When the sigmoidal curve was obtained by the curve fitting to the data, the determination coefficient was R2 = 0.79 and the 95% interval of the predicted Fa values was about +/- 24% for all drugs tested in the present study. For comparison, the permeated amount was calculated by multiplying the permeability of each drug (in vitro Papp) by the solubility in FaSSIF(mod). However, the calculated permeated amount showed a lower correlation with the observed human Fa compared to the observed permeated amount in the D/P system. The ratio of the observed permeated amount to the calculated permeated amount was in inverse proportion to the ratio of solubility in FaSSIF(mod) to solubility in TM. This finding suggests the necessity of determining the free fraction of the dissolved drug in the gastrointestinal (GI) tract when calculating the human Fa. In the case of the D/P system, since applied drugs dissolved in FaSSIF(mod) first, and then only the free fraction permeated the membrane, an accurate estimation of the human Fa was possible from only the observed permeated amount. This in vitro system is expected to contribute to the selection of better compounds for oral use during the lead- and formulation-optimization processes in the drug discovery stage.
机译:为了提高口服药物开发的成功率,在药物发现阶段需要一种体外方法,该方法可以准确地估计人类口服从固体制剂中吸收的多种化合物。溶出/渗透(D / P)系统是一种体外系统,可同时评估口服药物的溶出和渗透过程。在这项研究中,我们研究了D / P系统的优点,该系统通过以固态形式应用在人体对药物(吸收级分,Fa)的口服吸收的临时估计中。装有Madin-Darby犬肾(MDCK)II细胞单层的D / P系统用于同时评估48种市售药物的溶解量和渗透量(剂量的百分比)。稍加修改的,禁食状态的模拟肠液(FaSSIF(mod),8 mL)用作D / P系统的根尖介质。每种测试药物均以临床剂量的一百分之一的悬浮液形式应用于D / P系统的顶端。在缓冲溶液(pH 6.5)中估计了跨MDCK II细胞单层的表观渗透系数。通过烧瓶摇动法在pH 6.5下测量辛醇/水的分配系数(Log D)。运输介质(TM,pH 6.5)是从FaSSIF(mod)中除去卵磷脂和牛磺胆酸盐的缓冲溶液,用于确定药物施用后24小时的溶解度。在TM中的溶解度用作FaSSIF(mod)中的游离药物浓度。在D / P系统中观察到的人类Fa与渗透量之间具有良好的相关性。通过对数据进行曲线拟合获得S形曲线时,本研究中所有测试药物的测定系数为R2 = 0.79,预测Fa值的95%区间约为+/- 24%。为了比较,通过将每种药物(体外Papp)的渗透性乘以FaSSIF(mod)中的溶解度来计算渗透量。但是,与在D / P系统中观察到的渗透量相比,计算出的渗透量与观察到的人Fa显示出较低的相关性。观察到的渗透量与计算出的渗透量之比与FaSSIF(mod)中的溶解度与TM中的溶解度之比成反比。这一发现表明,在计算人Fa时,必须确定胃肠道(GI)中溶解药物的游离分数。在D / P系统的情况下,由于先将溶解在FaSSIF(mod)中的药物溶解,然后仅游离部分渗透到膜中,因此仅从观察到的渗透量就可以准确估计人Fa。该体外系统有望在药物发现阶段的前导和配方优化过程中,为口服更好的化合物的选择做出贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号